Statin Therapy in Women: What the Evidence Says About Who Benefits

Statins are among the most prescribed medications in the world, and the evidence supporting their use in people with established cardiovascular disease is among the most substantial in all of clinical medicine. But the question of who specifically benefits from statin therapy, particularly in the primary prevention setting, is more nuanced than the ubiquity of the prescription might suggest. For women, several layers of complexity apply: the evidence base was built predominantly on trials enrolling mostly men, absolute risk calculations systematically underestimate cardiovascular risk in women, sex-specific side effect profiles differ in meaningful ways, and a set of female-specific risk factors are not captured in standard risk equations at all.

Understanding the evidence around statin therapy in women is not an exercise in academic nuance. It has direct implications for which women are undertreated, which are appropriately treated, and which may have tolerable side effects managed away prematurely.

The Evidence Asymmetry: Secondary vs Primary Prevention

The clearest and most consistent evidence for statin benefit in women comes from secondary prevention, meaning treatment after a cardiovascular event has already occurred. In women with established coronary artery disease, a prior myocardial infarction, a history of stroke or transient ischemic attack, or peripheral artery disease, statins reduce the risk of subsequent major cardiovascular events. This benefit is well demonstrated and the recommendation to treat is strong and consistent across major guidelines.

The more contested territory is primary prevention: using statins in women who have not yet had a cardiovascular event. In this setting, the absolute benefit of statins is real but smaller in magnitude than in secondary prevention, and the absolute risk reduction differs between women and men because women tend to have lower baseline cardiovascular event rates at the ages most commonly targeted for primary prevention treatment.

This is not a case where statins fail to work in women. The relative risk reduction per unit of LDL lowering is similar across sexes. But the same relative reduction applied to a lower baseline risk produces a smaller absolute benefit. How small that absolute benefit needs to be before it no longer justifies treatment, considering side effects and individual patient preferences, is where clinical judgment enters.

The JUPITER Trial and What It Showed

The JUPITER trial examined rosuvastatin versus placebo in individuals with LDL below 130 mg/dL but elevated high-sensitivity C-reactive protein above 2 mg/L. Of the approximately 18,000 participants enrolled, about 38 percent were women, making it one of the better-powered trials for sex-specific analysis in a primary prevention population. 5 / Solid

In women enrolled in JUPITER, rosuvastatin produced statistically significant reductions in the composite cardiovascular endpoint. The relative risk reduction in women was similar to that in men. However, the absolute baseline risk in women was lower than in men, which meant the absolute risk reduction and the number needed to treat were less favorable in women than in men within the trial. This finding has been used to argue both for and against aggressive primary prevention statin use in women, depending on how one weights relative versus absolute benefit and how one views inflammation-driven risk as a modifier.

The practical implication is that high-sensitivity CRP elevation may be a useful risk-enhancing factor in women who are borderline for primary prevention statin therapy, particularly postmenopausal women in whom inflammatory burden may be a more dominant cardiovascular driver than in younger women.

What the Cholesterol Treatment Trialists Showed

The most comprehensive analysis of statin efficacy across sexes comes from the Cholesterol Treatment Trialists Collaboration, which pooled individual participant data from large randomized controlled trials of statin therapy. The CTT analysis examined outcomes per 1 mmol/L reduction in LDL cholesterol, separately in women and men. 5 / Solid

The finding was that the proportional reduction in major cardiovascular events per unit of LDL lowering was statistically similar in women and men. Statins do not work less well in women in relative terms. The absolute benefit, however, is determined by baseline risk, and because women had lower absolute event rates in many of the constituent trials, their absolute benefit was numerically smaller. This analysis provides the mechanistic foundation for the current consensus: statins should be used in women with high enough baseline risk to generate meaningful absolute benefit, and the question is identifying who those women are.

Risk Calculators and Why They Underestimate Risk in Women

The Pooled Cohort Equations, the risk estimation tool embedded in current ACC/AHA guidelines for primary prevention statin decisions, were derived from cohort studies that have well-documented limitations in women. The equations were developed from predominantly white and Black American cohorts and have less validation in other ethnic groups. They also systematically miss a set of cardiovascular risk factors that are uniquely or disproportionately relevant to women.

Several data show that the Pooled Cohort Equations underestimate cardiovascular risk in women who have experienced pregnancy complications, who underwent premature menopause, or who carry autoimmune conditions associated with accelerated atherosclerosis. A woman who scores at 7 percent 10-year cardiovascular risk by the Pooled Cohort Equations may in fact carry a substantially higher true risk when her complete clinical history is considered.

USPSTF 2022 guidelines recommend statins for adults aged 40 to 75 with one or more cardiovascular risk factors and a calculated 10-year ASCVD risk of 10 percent or higher. This threshold is reasonable as a starting point, but it should not be applied in isolation in women without considering whether the risk calculator has captured her complete risk burden.

Female-Specific Risk Factors That Guidelines Now Recognize

A growing body of evidence has established several conditions that occur exclusively or predominantly in women and that confer cardiovascular risk beyond what standard risk factors capture. Current AHA guidelines explicitly recognize these as risk-enhancing factors that warrant consideration of statin therapy at lower calculated risk thresholds than would otherwise apply.

Preeclampsia and hypertensive disorders of pregnancy are associated with a two- to fourfold increase in lifetime risk of coronary artery disease, heart failure, and stroke. The mechanism involves persistent endothelial dysfunction and accelerated atherosclerosis that persist long after the pregnancy has ended. A woman who had severe preeclampsia at age 28 carries cardiovascular risk that her 10-year Pooled Cohort Equation score at age 45 will not reflect.

Premature menopause, defined as natural or surgical menopause before age 40, is associated with increased cardiovascular risk independent of other factors. The loss of estrogen’s cardioprotective effects at a younger age than the general female population compresses the window of hormonal protection and exposes the cardiovascular system to estrogen-depleted conditions for a longer interval of life.

Autoimmune conditions including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are associated with accelerated atherosclerosis through chronic systemic inflammation and immune-mediated vascular injury. These conditions are substantially more prevalent in women than in men. A woman with moderate rheumatoid arthritis and a calculated 8 percent 10-year ASCVD risk carries meaningfully more cardiovascular burden than her calculated score suggests.

Gestational diabetes is associated with a substantially increased lifetime risk of type 2 diabetes and with cardiovascular risk that is independent of subsequent diabetes development. Women with a history of gestational diabetes warrant more proactive cardiovascular risk management than their current biomarkers alone might indicate.

Muscle Symptoms: Real, Frequently Misunderstood

Myalgia, defined as muscle aching or weakness attributed to statin therapy without enzyme elevation, is the most common side effect reported by patients on statins. In clinical trials using systematic symptom assessment, rates of myalgia in the active treatment arm often do not differ significantly from placebo, a finding that has led some to question whether most statin-associated myalgia is genuinely pharmacological. Nonetheless, in real-world clinical practice, muscle symptoms are a leading reason for statin discontinuation, and women report these symptoms at roughly 1.5 to 2 times the rate reported by men.

The reasons for this sex difference in symptom reporting are not fully established. Potential contributors include differences in body composition affecting tissue drug distribution, differences in the expression of drug transporter proteins and metabolic enzymes including CYP3A4, and differences in pain sensitivity and symptom reporting patterns. It is also possible that some of the reported sex difference reflects ascertainment bias, as women may be more attentive to and forthcoming about physical symptoms in clinical contexts.

True statin-induced myopathy with creatine kinase elevation above 10 times the upper limit of normal, a condition called rhabdomyolysis when severe, is rare and does not appear to differ substantially by sex in its frequency. The clinical problem that affects women disproportionately is myalgia without significant CK elevation, which may be less serious in terms of tissue injury but can substantially reduce quality of life and adherence.

Lipophilic statins, including atorvastatin and simvastatin, penetrate muscle tissue more readily than hydrophilic statins such as rosuvastatin and pravastatin. Some cardiologists switch patients with myalgia from lipophilic to hydrophilic statins as a management strategy, though the evidence that this improves tolerability is mixed and inconsistent across studies. Nonetheless, this is a reasonable clinical maneuver before concluding that a patient cannot tolerate any statin.

Dose reduction and alternate-day dosing strategies have evidence supporting their use in statin-intolerant patients. Rosuvastatin in particular has a sufficiently long half-life to make alternate-day or even twice-weekly dosing pharmacologically plausible, and small studies have suggested that this approach can maintain meaningful LDL reduction while reducing muscle symptoms in intolerant patients.

Statin Therapy and Diabetes Risk in Women

Statins modestly increase the risk of new-onset type 2 diabetes, an effect that has been documented across multiple trials and meta-analyses. The relative risk increase is approximately 10 percent above baseline, which translates to roughly one excess case of diabetes per 100 to 200 patients treated per year depending on baseline risk. This risk appears to be higher in postmenopausal women than in premenopausal women, possibly because postmenopausal metabolic shifts have already reduced insulin sensitivity.

The clinical framework for communicating this risk is important. For a woman with established cardiovascular disease or very high cardiovascular risk taking a statin for secondary prevention, the absolute cardiovascular benefit of statin therapy substantially outweighs the diabetes risk in virtually all cases. For a woman at lower absolute cardiovascular risk being considered for primary prevention, the risk-benefit calculation is closer and should be discussed explicitly as part of shared decision-making.

Women who develop diabetes while on statin therapy should not necessarily discontinue the statin. The development of diabetes itself increases cardiovascular risk and may actually strengthen the indication for continued statin therapy. The diabetes should be managed with appropriate lifestyle and pharmacological intervention while statin therapy continues.

Pregnancy and Women of Childbearing Age

Statins are contraindicated during pregnancy. Although the mechanistic concern about fetal harm from cholesterol synthesis inhibition during fetal development has not been definitively proven in human observational data, the potential risk and the availability of alternatives for temporary lipid management during pregnancy make statin discontinuation the appropriate standard of care.

Women of reproductive age who are on statins should receive explicit counseling about the need to discontinue therapy if pregnancy is planned or discovered, and should have a plan in place for managing lipid levels during pregnancy if clinically significant hypercholesterolemia is present. Bile acid sequestrants are generally considered the safest lipid-lowering option during pregnancy for women who require pharmacological intervention.

For women with familial hypercholesterolemia, whose risk from untreated severely elevated LDL is substantial, the management of pregnancy in the context of statin discontinuation warrants involvement of a cardiologist and a high-risk obstetric team.

Using Coronary Artery Calcium Score to Inform Decisions

The coronary artery calcium score, measured by non-contrast CT imaging, provides a direct quantification of atherosclerotic calcification in the coronary arteries and has emerged as a powerful tool for refining cardiovascular risk estimation beyond what calculated risk scores provide. For women who are uncertain about starting a statin, particularly those in the intermediate calculated risk range of 7.5 to 20 percent 10-year ASCVD risk, calcium scoring can substantially shift the clinical conversation.

A CAC score of zero, meaning no detectable coronary calcification, identifies a group of women at very low near-term cardiovascular event risk in whom statin initiation can be reasonably deferred in favor of continued lifestyle management and repeat risk assessment. A CAC score above 100 or above the 75th percentile for age and sex supports initiating statin therapy even in women who are ambivalent or borderline by calculated risk alone. A score between 1 and 99 provides less definitive guidance but can inform a shared decision-making discussion about individual risk tolerance and values.

The calcium score is particularly useful in women precisely because the Pooled Cohort Equations have the most uncertainty in this group. A woman who calculates to 9 percent 10-year risk but has a CAC of 200 is carrying substantially more subclinical atherosclerotic burden than her calculated score reflects, and that information should change the treatment conversation.

The Role of Lipoprotein(a)

Lipoprotein(a), abbreviated Lp(a), is a genetically determined lipoprotein particle that is an independent risk factor for cardiovascular disease, particularly in women with premature atherosclerosis. Lp(a) is notably elevated in a substantial minority of women, and its levels are not substantially modified by statin therapy. This means that a woman on a statin who has high Lp(a) is receiving effective LDL-lowering but not addressing a separate, significant contributor to her cardiovascular risk.

Current guidelines recommend measuring Lp(a) at least once in adults, particularly those with a family history of premature cardiovascular disease, unexplained early cardiovascular events in the absence of traditional risk factors, or familial hypercholesterolemia. In a woman with very high Lp(a) who appears to have otherwise well-controlled cardiovascular risk factors on statin therapy, this finding supports consideration of additional risk reduction strategies including intensified LDL lowering with PCSK9 inhibition, aggressive blood pressure control, and aspirin use in appropriate clinical contexts pending further evidence from ongoing Lp(a)-specific trials.

A Conversation Worth Having

For many women, the question of whether to start a statin is not straightforwardly settled by plugging numbers into a calculator. The decision involves understanding her actual risk profile, including elements the calculator may not capture; understanding the evidence for benefit and the realistic magnitude of that benefit at her specific risk level; and understanding the side effect profile, particularly muscle symptoms, in a way that allows her to make an informed choice and to persist through a structured rechallenge if symptoms develop.

Clinicians who approach this conversation with the complexity it deserves, neither dismissing statin benefits in women because primary prevention trials enrolled mostly men, nor overestimating those benefits in every woman above a threshold age, will serve their patients most effectively. The evidence base is rich enough to support individualized decision-making. Using it well means understanding not just what the trials found, but who was in those trials and how the findings translate to the woman sitting across the desk.

The Women’s Signal Check is fifteen questions mapping the female cardiovascular risk pattern, including reproductive history, microvascular signals, and the factors standard risk calculators do not capture. It produces a specific starting point for your next clinical conversation.